Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07)

Christoph Mamot, Dirk Klingbiel, Felicitas Hitz, Christoph Renner, Thomas Pabst, Christoph Driessen, Ulrich Mey, Miklos Pless, Mario Bargetzi, Fatime Krasniqi, Federica Gigli, Thomas Hany, Andrei Samarin, Christine Biaggi, Corinne Rusterholz, Stephan Dirnhofer, Emanuele Zucca, Giovanni Martinelli

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: Our main objective was to prospectively determine the prognostic value of [18F]fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) after two cycles of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone given every 14 days (R-CHOP-14) under standardized treatment and PET evaluation criteria. Patients and Methods: Patients with any stage of diffuse large B-cell lymphoma were treated with six cycles of R-CHOP-14 followed by two cycles of rituximab. PET/CT examinations were performed at baseline, after two cycles (and after four cycles if the patient was PET-positive after two cycles), and at the end of treatment. PET/CT examinations were evaluated locally and by central review. The primary end point was event-free survival at 2 years (2-year EFS). Results: Median age of the 138 evaluable patients was 58.5 years with a WHO performance status of 0, 1, or 2 in 56%, 36%, or 8% of the patients, respectively. By local assessment, 83 PET/CT scans (60%) were reported as positive and 55 (40%) as negative after two cycles of R-CHOP-14. Two-year EFS was significantly shorter for PET-positive compared with PET-negative patients (48% v 74%; P = .004). Overall survival at 2 years was not significantly different, with 88% for PET-positive versus 91% for PET-negative patients (P = .46). By using central review and the Deauville criteria, 2-year EFS was 41% versus 76% (P <.001) for patients who had interim PET/CT scans after two cycles of R-CHOP-14 and 24% versus 72% (P <.001) for patients who had PET/CT scans at the end of treatment. Conclusion: Our results confirmed that an interim PET/CT scan has limited prognostic value in patients with diffuse large B-cell lymphoma homogeneously treated with six cycles of R-CHOP-14 in a large prospective trial. At this point, interim PET/CT scanning is not ready for clinical use to guide treatment decisions in individual patients.

Original languageEnglish
Pages (from-to)2523-2529
Number of pages7
JournalJournal of Clinical Oncology
Volume33
Issue number23
DOIs
Publication statusPublished - Aug 10 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07)'. Together they form a unique fingerprint.

Cite this